Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis

Open access
van Linde, Myra E., Brahm, Cyrillo G., de Witt Hamer, Philip C., Reijneveld, Jaap C., Bruynzeel, Anna M. E., Vandertop, W. Peter, van de Ven, Peter M., Wagemakers, Michiel, van der Weide, Hiske L., Enting, Roelien H., Walenkamp, Annemiek M. E., Verheul, Henk M. W. · 2017 · Journal of Neuro-Oncology

Abstract

Glioblastoma multiforme (GBM) universally recurs with dismal prognosis. We evaluated the efficacy of standard treatment strategies for patients with recurrent GBM (rGBM). From two centers in the Netherlands, 299 patients with rGBM after first-line treatment, diagnosed between 2005 and 2014, were retrospectively evaluated. Four different treatment strategies were defined: systemic treatment (SYST), re-irradiation (RT), re-resection followed by adjuvant treatment (SURG) and best supportive care (BSC). Median OS for all patients was 6.5 months, and median PFS (excluding patients receiving BSC) was 5.5 months. Older age, multifocal lesions and steroid use were significantly associated with a shorter survival. After correction for confounders, patients receiving SYST (34.8%) and SURG (18.7%) had a significantly longer survival than patients receiving BSC (39.5%), 7.3 and 11.0 versus 3.1 months, respectively [HR 0.46 (p < 0.001) and 0.36 (p < 0.001)]. Median survival for patients receiving RT (7.0%) was 9.2 months, but this was not significantly different from patients receiving BSC (p = 0.068). Patients receiving SURG compared to SYST had a longer PFS (9.0 vs. 4.3 months, respectively; p < 0.001), but no difference in OS was observed. After adjustments for confounders, patients with rGBM selected for treatment with SURG or SYST do survive significantly longer than patients who are selected for BSC based on clinical parameters. The value of reoperation versus systemic treatment strategies needs further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11060-017-2564-z

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 202

Metadata

Authors
van Linde, M. E., Brahm, C. G., de Witt Hamer, P. C., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., van de Ven, P. M., Wagemakers, M., van der Weide, H. L., Enting, R. H., Walenkamp, A. M. E., & Verheul, H. M. W.
Venue
Journal of Neuro-Oncology
Published
2017-07-20
Volume
135
Issue
1
Pages
183-192
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2558944992
Cited by
202
References
3
FWCI
7.63
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. https://app.cochat.ai/papers/10.1007/s11060-017-2564-z
The paper
van Linde, M. E., Brahm, C. G., de Witt Hamer, P. C., Reijneveld, J. C., Bruynzeel, A. M. E., Vandertop, W. P., van de Ven, P. M., Wagemakers, M., van der Weide, H. L., Enting, R. H., Walenkamp, A. M. E., & Verheul, H. M. W. (2017). Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-017-2564-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.